Vestronidase Alfa

證據等級: L5

預測適應症: 10 個

Vestronidase Alfa: From Mucopolysaccharidosis VII to Scheie Syndrome

One-Sentence Summary

Vestronidase alfa is a recombinant human beta-glucuronidase enzyme replacement therapy, originally developed for Mucopolysaccharidosis type VII (MPS VII, Sly syndrome). The TxGNN model’s top-ranked prediction suggests possible efficacy in Scheie syndrome, but currently no clinical trials and no published literature support this specific indication.

Quick Overview

Item	Content
Original Indication	Mucopolysaccharidosis type VII (MPS VII, Sly syndrome) — per literature evidence (approved in US/EU); not registered in Denmark in this evidence pack
Predicted New Indication	Scheie syndrome
TxGNN Prediction Score	99.90%
Evidence Level	L5
Denmark Market Status	Not Marketed
Number of Marketing Authorisations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (data gap). Based on known information, vestronidase alfa is a recombinant human beta-glucuronidase (GUS) enzyme replacement therapy; its efficacy in Mucopolysaccharidosis VII — caused by GUS deficiency — is well established per the literature evidence in this pack.

However, Scheie syndrome is the attenuated form of Mucopolysaccharidosis type I (MPS I), which is caused by deficiency of a different enzyme, alpha-L-iduronidase, not beta-glucuronidase. This is an important mechanistic mismatch: unlike MPS VII, vestronidase alfa does not target the enzyme deficient in MPS I. Consistent with this, no supporting clinical trials or literature were found for this specific drug-disease pair. The evaluator’s rationale for other ontology-adjacent predictions in this batch (e.g., “lysosomal storage disease with skeletal involvement”) explicitly flags that TxGNN may be surfacing broad mucopolysaccharidosis-family ontology overlap with the drug’s existing MPS VII indication, rather than a genuinely novel signal — the same caution likely applies here.

Notably, other candidates in this same evidence batch have materially stronger support: Hurler syndrome (also MPS I, but linked to an active prenatal enzyme-replacement trial, NCT04532047) and Sanfilippo syndrome (MPS III, supported by 4 literature citations, though these describe vestronidase alfa’s MPS VII data rather than direct Sanfilippo studies). Given the top-ranked Scheie syndrome prediction has zero direct evidence, these alternative candidates may warrant separate, more thorough evaluation.

Clinical Trial Evidence

Currently no related clinical trials registered.

Literature Evidence

Currently no related literature available.

Denmark Market Information

Vestronidase alfa is not marketed in Denmark — no marketing authorisations (national or centralised/EMA) are recorded in this evidence pack.

Safety Considerations

Please refer to the approved Summary of Product Characteristics (SmPC) for safety information.

Conclusion and Next Steps

Decision: Hold

Rationale:

The top-ranked predicted indication (Scheie syndrome) has no supporting clinical trials or literature, and its underlying enzyme deficiency (alpha-L-iduronidase) does not match vestronidase alfa’s target enzyme (beta-glucuronidase), raising concern that this is an ontology-overlap artifact rather than a genuine repurposing signal.

To proceed, the following is needed:

TFDA/Danish SmPC warnings and contraindications (blocking data gap, required for S1 safety screening)
Mechanism of action (MOA) confirmation via DrugBank (high-priority data gap)
Targeted literature/trial search specifically for vestronidase alfa in Scheie syndrome (MPS I)
Consideration of a separate evaluation for Hurler syndrome (active trial NCT04532047) and Sanfilippo syndrome, which show more supporting evidence than the top-ranked candidate
Confirmation of Denmark market/registration status, given current “Not Marketed” flag
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.